//php if ($breadcrumb): print $breadcrumb; endif; ?>
Englerin A
Protein target name:
TRPC4, TRPC5
Mechanism of action:
AgonistInduces TRPC4/5-dependent calcium ion influx and cell death
Recommended Concentration for use in cells:
10-1,000 nM
Probe Information
In vitro validation
Structure-activity relationship:
SAR data are available based on compound-induced cytotoxicity in A498 cells (comparison in IC50 values for inhibition of cell viability).
The cinnamic ester part can be modified to yield more potent derivatives.
Replacement of the isoprpyl group by ethyl or methyl group decreases the activity.
Modifications of the glycolic ester lead to decrease in potency.
Probe Selectivity in Vitro:
Englerin A (1 µM) was assayed for inhibition of selected protein kinases (SelectScreen Kinase Profling), GPCRs (GPCRProfiler® services of EMD Millipore) and ion channels (Ion Channel Profiler Services of EMD Millipore). Only weak activity was observed against some of these proteins: ca. 30% inhibition of GPR109A and 15% inhibition of hERG.
In cell validation
Potency in cells:
EC50
TRPC4: 11.2 nM, TRPC5: 7.6 nM
Potency assay (cells):
Measurements of the free intracellular calcium ion concentrations using the Fura-2-AM at an extracellular Ca2+ concentration of 1.5 mM in HEK293 cells conditionally expressing human TRPC4 or TRPC5. In A498 cells, which only express TRPC4, EC50=10 nM, and this activity was sensitive to the TRPC4 inhibitor, ML204.
Off target protein and potency (cells):
TRPC6, TRPM2, TRPV4
Potency assay, off target (cells):
No (agonistic) activity of Englerin A was detected in HEK293 cells overexpressing TRPC6, TRPM2 or TRPV4. The activity was assessed based on Ca2+ level measurements at a compound concentration of 1 µM.
Toxicity
Cytoxicity assay:
Yes
Notes on cytotoxicity:
Cytotoxicity was determined by means of metabolic activity (using a WST1 reagent) in A498 cells upon compound addition for 48 h or 4 h.
IC50 (4 h incubation)=17 nM; IC50 (48 h incubation)=45 nM.
Englerin A was assayed for growth inhibition using the NCI-60 cancer cell panel (see http://pubs.acs.org/doi/abs/10.1021/ol802339w).